Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11522248 | 0.83 | APEX1 (0.58) | APEX1BLMTP53SMN1; SMN2LMNA | |
| SCHEMBL14426907 | 0.80 | APEX1 (0.68) | APEX1BLMTP53SMN1; SMN2POLB | |
| SCHEMBL21389109 | 0.79 | APEX1 (0.62) | APEX1BLMTP53SMN1; SMN2LMNA | |
| SCHEMBL27888173 | 0.79 | APEX1 (0.62) | APEX1BLMTP53SMN1; SMN2LMNA | |
| SCHEMBL21389170 | 0.79 | APEX1 (0.62) | APEX1BLMTP53SMN1; SMN2LMNA | |
| SCHEMBL10582437 | 0.79 | APEX1 (0.57) | APEX1BLMTP53SMN1; SMN2LMNA | |
| SCHEMBL3178292 | 0.78 | APEX1 (0.70) | APEX1BLMTP53SMN1; SMN2POLB | |
| SCHEMBL19119195 | 0.78 | APEX1 (0.70) | APEX1BLMTP53SMN1; SMN2POLB | |
| SCHEMBL3178301 | 0.78 | APEX1 (0.70) | APEX1BLMTP53SMN1; SMN2POLB | |
| SCHEMBL9628959 | 0.78 | APEX1 (0.69) | APEX1BLMTP53SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014122575-A2 | FATTY ACID CONJUGATES FOR THE TREATMENT OF INFLAMMATION AND METABOLIC DISEASES | KANDULA MAHESH (IN) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014106805-A2 | FATTY ACID CONJUGATES AND THEIR USES | KANDULA MAHESH (IN) | 2014-07-10 | — | — | WO | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | APEX1 3565/4885BLM 3726/4885TP53 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.